Byrne Asset Management LLC Cytom X Therapeutics, Inc. Transaction History

Byrne Asset Management LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 21, 2023	BUY	$1.41 - $1.92 $564 - $768	400 Added 5.26%	8,000 $13,000
Q1 2023 Apr 17, 2023	SELL	$1.48 - $2.88 $9,620 - $18,720	-6,500 Reduced 46.1%	7,600 $11,000
Q4 2022 Jan 30, 2023	BUY	$1.19 - $1.91 $16,779 - $26,931	14,100 New	14,100 $22,000

50.2M

22.3K

22.9K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $79.1M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Byrne Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Byrne Asset Management LLC with notifications on news.